Free Trial

Gritstone bio Q1 2023 Earnings Report

Gritstone bio EPS Results

Actual EPS
-$0.30
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Gritstone bio Revenue Results

Actual Revenue
$2.44 million
Expected Revenue
$4.00 million
Beat/Miss
Missed by -$1.56 million
YoY Revenue Growth
N/A

Gritstone bio Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Healthcare Takes A Big Step Forward With The Help of A.I. (Ad)

To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.

Click here to learn more about the booming eHealth industry - and see which microcap will be at the

Gritstone bio Earnings Headlines

Gritstone Oncology Inc (GRTSQ)
Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
Gritstone bio, Inc. (GRTSQ)
Firm Retention Summary: Gritstone bio
See More Gritstone bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Gritstone bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gritstone bio and other key companies, straight to your email.

About Gritstone bio

Gritstone bio (NASDAQ:GRTS), a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

View Gritstone bio Profile

More Earnings Resources from MarketBeat

Upcoming Earnings